TITLE

Parathyroid hormone (1-84) plus alendronate was not better than monotherapy with either agent in postmenopausal osteoporosis: COMMENTARY

AUTHOR(S)
Jamal, Sophie
PUB. DATE
May 2004
SOURCE
ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p62
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Alendronate inhibits bone resorption, increases bone mineral density (BMD), and reduces fracture risk in men and women with osteoporosis. Parathyroid hormone therapy (PTH) administered daily stimulates bone formation and increases BMD in both men and postmenopausal women with osteoporosis. PTH also reduces fracture risk in postmenopausal women. The different mechanisms of action of PTH and alendronate led to the plausible hypothesis that the combination of these agents would lead to a greater increase in BMD than either agent alone. In both studies, areal BMD was assessed using dual-energy x-ray absorptiometry and volumetric BMD was assessed with quantitative computed tomography.
ACCESSION #
13221827

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics